European CHMP recommends approval of icosapent ethyl (Vazkepa) for reduction of cardiovascular events in patients at high cardiovascular risk

This lipid modifying agent is intended to be licensed to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk with elevated triglycerides (≥150 mg/dL) and established CV disease, or diabetes, and at least one other CV risk factor.

Source:

European Medicines Agency